Profound Medical Corp.
About Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $16.1M
- Net income
- -$42.6M
- Total assets
- $77.5M
- Market cap
- $242.0M
- Gross margin
- 70.8%
- Operating margin
- -256.3%
- Net margin
- -264.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $16.1M
- Cost of revenue
- $4.7M
- Gross profit
- $11.4M
- Operating expenses
- $52.6M
- Operating income
- -$41.3M
- Income tax
- $252.0K
- Net income
- -$42.6M
- EPS (basic)
- $1.41
- EPS (diluted)
- $1.41
Balance sheet
- Total assets
- $77.5M
- Current assets
- $76.1M
- Total liabilities
- $11.0M
- Current liabilities
- $6.1M
- Shareholders’ equity
- $66.4M
Cash flow
- Operating cash flow
- -$38.2M
- Investing cash flow
- -$242.0K
- Financing cash flow
- $41.1M
- Net cash flow
- $2.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $242.0M
- P/E ratio
- 4.7
- EPS (diluted)
- $1.41
- Shares outstanding
- 36.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $42.6M in FY2025.
- Revenue grew 51% from FY2024 to FY2025.
- Gross margin of 70.8%, net margin -264.4%.
- Trading 24% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Profound Medical Corp..
Write a review
News about Profound Medical Corp.
News & sentiment via Polygon.io
